Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has reportedly raised hundreds of millions of renminbi in a Series B financing round led by Weigao Holding’s fund. The proceeds will be used for product research and development and facilities construction.
Company Background
Founded in 2016 and incubated by the Institute of Advanced Technology at the University of Science and Technology of China, Tongling Bionic has received support from Anhui Provincial Emerging Industry Investment, Chinese Academy of Sciences Venture Capital, Zhejiang University Venture Capital, and other prominent investment institutions.
Product Development
Tongling Bionic took the lead in China’s research and development of interventional cardiac catheterization pumps in 2017 and completed the inspection of its miniature cardiac catheter pump in the first half of this year. The company also developed the intra-aortic balloon counter-pulsation system (IABP), external counter-pulsation therapy system, non-invasive cardiac output monitor, extracorporeal membrane oxygenation device (ECMO), and other innovative products for heart failure treatment.-Fineline Info & Tech
